| tenofovir disoproxil fumarate / Generic mfg. |
NCT05238844: A Study of Safety and Efficacy of ATI-2173 and Vebicorvir in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection |
|
|
| Terminated | 2a | 2 | RoW | ATI-2173 25mg, Vebicorvir 300mg, Viread 300Mg Tablet | Antios Therapeutics, Inc | Chronic Hepatitis b | 05/22 | 05/22 | | |
NCT04847440: A Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus Coinfection |
|
|
| Terminated | 2a | 40 | RoW | ATI-2173, Viread, tenofovir disoproxil fumarate, AB-729 | Antios Therapeutics, Inc | Hepatitis B, Chronic, Hepatitis D | 09/22 | 09/22 | | |
ACTRN12613000946718: A study of peginterferon-alfa intervention to achieve hepatitis B surface antigen loss in multi-drug resistant chronic hepatitis B participants under long-term viral suppression with tenofovir DF +/- lamivudine salvage therapy (TDF-109 cohort)
|
|
|
| Not yet recruiting | 2 | 55 | | | Peter Angus, Gilead, Roche | Chronic hepatitis B | | | | |
ACTRN12606000381583: An Open-Label Study Evaluating the Antiviral Activity of Tenofovir Disoproxil Fumarate (DF) 300mg in Patients with Chronic Hepatitis B Infection and Persistent Viral Replication after Long-Term Therapy with Adefovir Dipivoxil 10mg Daily |
|
|
| Recruiting | 2 | 60 | | | Austin Health (investigator initiated), Gilead, Austin Health, Monash Medical Centrre, The Alfred, St Vincent's, Royal Melbourne, The Western hospital, RPA | Hepatitis B | | | | |
NCT00033163: A Comparison of Adefovir and Tenofovir for the Treatment of Lamivudine-Resistant Hepatitis B Virus in People With HIV |
|
|
| Completed | 2 | 90 | US | Adefovir dipivoxil, Tenofovir disoproxil fumarate | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections, Hepatitis B | | 05/05 | | |
NCT01334567: Rollover Protocol Continued Access to Tenofovir Disoproxil Fumarate (TDF) for Subjects in Taiwan |
|
|
| Completed | 2 | 30 | RoW | Tenofovir DF, Viread® | Gilead Sciences | Hepatitis B | 12/13 | 12/13 | | |
2014-003894-41: Effect of Interferon on protecting immune response in chronic hepatitis B patients under treatment for the infection with standard antiviral therapy Effetto dell’Interferone sulla risposta immunitaria proteggente in pazienti con epatite B cronica già in trattamento per l’infezione con terapia antivirale standard |
|
|
| Ongoing | 2 | 80 | Europe | Peginterferone alfa-2a, Entecavir, Tenofovir Disoproxil, Solution for injection in pre-filled syringe, Tablet, Pegasys, Baraclude, Viread | Azienda Ospedaliero-Universitaria di Parma, F. Hoffmann - La Roche Ltd, Gilead Sciences srl, Regione Emilia-Romagna | Chronic hepatitis B infection Infezione da Epatite B cronica, Chronic hepatitis B infection Infezione da Epatite B cronica, Diseases [C] - Virus Diseases [C02] | | | | |
NCT02174276 / 2014-001011-39: Safety and Efficacy of GS-4774 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Participants With Chronic Hepatitis B (CHB) and Who Are Currently Not on Treatment |
|
|
| Completed | 2 | 195 | Canada, US, Europe, RoW | Tenofovir disoproxil fumarate, TDF, Viread®, GS-4774 | Gilead Sciences | Chronic Hepatitis B | 02/16 | 05/18 | | |
NCT02452528: Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus |
|
|
| Terminated | 2 | 4 | US | ARC-520, Placebo, Entecavir, Baraclude, Tenofovir, Viread, diphenhydramine | Arrowhead Pharmaceuticals | Chronic Hepatitis B | 12/16 | 12/16 | | |
| Terminated | 2 | 79 | Europe, RoW | ARC-520, entecavir, Baraclude, pegylated interferon alpha 2a, Peginterferon, Pegasys, tenofovir disoproxil, Viread, antihistamine | Arrowhead Pharmaceuticals | Hepatitis B, Hepatitis D | 12/16 | 12/16 | | |
NCT02579382 / 2015-002017-30: Study to Evaluate the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being Treated |
|
|
| Completed | 2 | 192 | Europe, Canada, US, RoW | TDF, Viread®, Vesatolimod, GS-9620, Placebo | Gilead Sciences | Chronic Hepatitis B | 01/17 | 05/19 | | |
| Completed | 2 | 70 | Europe | PEG-IFN alfa-2a, Tenofovir, Pegasys, Viread, PEG-IFN alfa-2a, placebo | HepNet Study House, German Liverfoundation, Hannover Medical School, Hoffmann-La Roche, Gilead Sciences | Hepatitis D | 08/17 | 08/17 | | |
NCT03546621: A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination With Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients With Chronic Hepatitis D |
|
|
| Completed | 2 | 120 | Europe, RoW | Myrcludex B, Myrcludex-B, Tenofovir, Viread | Hepatera Ltd., Data Matrix Solutions | Chronic Hepatitis D Infection With Hepatitis B | 01/18 | 01/18 | | |
| Not yet recruiting | 2 | 120 | Europe | Myrcludex B, Powder for solution for injection, Film-coated tablet, Viread | Hepatera LLC, Hepatera LLC | Chronic Hepatitis D, Chronic Hepatitis D infection, Diseases [C] - Digestive System Diseases [C06] | | | | |
2017-001647-12: A study to determine how safe the treatment is for subjects diagnosed with hepatitis B virus infections when combined with other treatments for hepatitis B. Subjects must have no evidence of liver damage. Un estudio para determinar la seguridad del tratamiento para los sujetos diagnosticados con infecciones por el virus de la hepatitis B cuando se combinan con otros tratamientos para la hepatitis B. Los sujetos no deben tener evidencia de daño hepático. |
|
|
| Ongoing | 2 | 20 | Europe | ARB-001467, Viread, Pegasys, ARB-001467, Solution for infusion, Film-coated tablet, Solution for injection in pre-filled syringe, Viread, Pegasys | Arbutus Biopharma Corporation, Arbutus Bipoharma Corporation | Hepatitis B virus e-antigen (HBeAg)-negative subjects with chronic hepatitis B virus infection (CHB) Pacientes con infección crónica por el virus de la hepatitis B (HBC) HBeAg-negativo sin cirrosis, Subjects infected with hepatitis B virus Los sujetos infectados con el virus de la hepatitis B, Diseases [C] - Virus Diseases [C02] | | | | |
NCT02565719: REP 2139-Mg and REP 2165-Mg Combination Therapy in Chronic Hepatitis B Infection |
|
|
| Completed | 2 | 40 | RoW | REP 2139-Mg, not availalble, Pegasys, pegylated interferon alpha-2a, Viread, tenofovir disoproxil fumarate, REP 2165-Mg, unaivalable | Replicor Inc. | Chronic Hepatitis B | 05/19 | 05/19 | | |
MYR 203, NCT02888106: Myrcludex B in Combination With Peginterferon Alfa-2a Versus Peginterferon Alfa-2a Alone in Patients With Chronic Viral Hepatitis B With Delta-agent |
|
|
| Completed | 2 | 90 | RoW | Myrcludex B, Bulevirtide, PEG IFN alfa-2a, Pegasys, Tenofovir, Viread | Hepatera Ltd. | Chronic Viral Hepatitis B With Delta-agent | 11/19 | 10/20 | | |
NCT04157699: An Study to Evaluate Safety and Efficacy of QL-007 Tablets in Combination With Tenofovir in Naive Patients With Chronic Hepatitis b |
|
|
| Recruiting | 2 | 100 | RoW | TDF tablet, Tenofovir disoproxil fumarate tablet, QL-007 | Qilu Pharmaceutical Co., Ltd. | Chronic Hepatitis b | 12/20 | 10/22 | | |
2021-001003-32: Controlled Interruption of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Infections Gecontroleerd staken van antivirale behandelingen in chronische hepatitis B infecties |
|
|
| Ongoing | 2 | 140 | Europe | Tablet, Baraclude, Entecavir KRKA, Tenofovir Disoproxil Mylan, Viread, Vemlidy | Antwerp University Hospital, Fonds Wetenschappelijk Onderzoek | Chronic Hepatitis B Infection Chronische hepatitis B infectie., Chronic Hepatitis B Infection. Chronische hepatitis B besmetting., Diseases [C] - Virus Diseases [C02] | | | | |
NCT04289987: A Study to Evaluate the Efficacy and Safety of Therapeutic Hepatitis B Vaccine |
|
|
| Completed | 2 | 134 | RoW | CVI-HBV-002, Normal Saline(placebo) | CHA Vaccine Institute Co., Ltd. | Hepatitis B, Chronic | 12/23 | 12/23 | | |
2021-002450-81: A Clinical Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Treatment With JNJ-73763989, Nucleos(t)ide Analogs, and Pegylated Interferon Alpha-2a in Patients With Chronic Hepatitis B Virus Infection. Estudio clínico para evaluar la eficacia, seguridad, tolerabilidad y farmacocinética del tratamiento con JNJ-73763989, análogos de nucleos(t)ido e interferón pegilado alfa-2a en pacientes con infección crónica por el virus de la hepatitis B. |
|
|
| Ongoing | 2 | 102 | Europe | JNJ-73763989, Solution for injection, Film-coated tablet, Solution for injection in pre-filled syringe, Entecavir Mylan 0.5 mg film-coated tablets, Viread 245 mg film-coated tablets, Vemlidy 25 mg film-coated tablets, Pegasys 180 micrograms solution for injection in pre-filled syringe | Janssen-Cilag International NV, Janssen Research and Development LLC | Chronic Hepatitis B Virus Infection Infección crónica por el virus de la hepatitis B, Chronic Hepatitis B Virus Infection Infección crónica por el virus de la hepatitis B, Diseases [C] - Virus Diseases [C02] | | | | |
2019-000622-22: A Clinical Study to Investigate the Efficacy and Safety of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection |
|
|
| Not yet recruiting | 2 | 450 | Europe | JNJ-56136379, JNJ-73763989, Solution for injection, Tablet, Film-coated tablet, Baraclude, Viread, Vemlidy | Janssen Sciences Ireland UC, Janssen Sciences Ireland Unlimited Company, Janssen Sciences Ireland UC, Janssen Sciences Ireland Unlimited Company, Janssen Cilag S.p.A. | Chronic Hepatitis B Virus Infection, Chronic Hepatitis B Virus Infection, Diseases [C] - Virus Diseases [C02] | | | | |
NCT04133259: Evaluate the Efficacy and Safety of HLX10 in Chronic Hepatitis B Patients |
|
|
| Recruiting | 2 | 44 | RoW | Recombinant anti-programmed death-1 (PD-1) humanized monoclonal antibody, HLX10 for Injection, HLX10, Nucleoside/nucleotide analogues, Entecavir, Tenofovir disoproxil fumarate | Henlix, Inc | Hepatitis B, Chronic | 04/22 | 07/22 | | |
NCT04114890: Tenofovir in Pregnancy to Prevent Mother to Child Transmission of Hepatitis B. |
|
|
| Completed | 2 | 27 | RoW | Tenofovir Disoproxil Fumarate | University of Oxford | Hepatitis B, Tenofovir, Pregnancy | 09/23 | 09/23 | | |
2020-003956-34: A Clinical Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Treatment With JNJ-73763989, JNJ-56136379, Nucleos(t)ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Patients With Chronic Hepatitis B Virus Infection. |
|
|
| Not yet recruiting | 2 | 50 | Europe | JNJ-73763989, Solution for injection, Film-coated tablet, Solution for injection in pre-filled syringe, Viread 245 mg film-coated tablets, Vemlidy 25 mg film-coated tablets, Entecavir Mylan 0.5 mg film-coated tablets, Pegasys 180 micrograms solution for injection in pre-filled syringe | Janssen-Cilag International NV, Janssen Research and Development LLC | Chronic Hepatitis B Virus Infection, Chronic Hepatitis B Virus Infection, Diseases [C] - Virus Diseases [C02] | | | | |
NCT04439539: A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection |
|
|
| Completed | 2 | 54 | Europe, Canada, Japan, US, RoW | JNJ-73763989, JNJ-3989, PegIFN-alpha-2a, Tenofovir disoproxil, Tenofovir alafenamide, JNJ-56136379, JNJ-6379 | Janssen Research & Development, LLC | Hepatitis B, Chronic | 08/23 | 02/24 | | |
NCT03109730: Phase 1b/2a Study of ABI-H0731 in Patients With Chronic Hepatitis B |
|
|
| Completed | 1b/2a | 38 | Europe, RoW | ABI-H0731, Placebo for ABI-H0731, Entecavir, ETV, Tenofovir Disoproxil Fumarate, TDF, Pegasys, peginterferon alfa-2a | Assembly Biosciences | Chronic Hepatitis B | 03/18 | 06/18 | | |
NCT02995005: Tenofovir in Early Pregnancy to Prevent Mother-to-child Transmission of Hepatitis B Virus |
|
|
| Completed | 1/2 | 98 | RoW | Tenofovir Disoproxil Fumarate, Viread | Johns Hopkins Bloomberg School of Public Health, Thrasher Research Fund, Shoklo Malaria Research Unit, Chiang Mai University, University of Oxford | Hepatitis B | 01/23 | 01/23 | | |
